Post Mortem Tissue Donation of Pediatric Tumor Tissues and Cells

NCT05120518 | Recruiting

• 1 other identifier: 2019-2982
• Study Type: observational
• Target: 150
• Locations: 1 country
• Sites: 1

Brief Summary

The objective of this study is to utilize all donated pediatric tumor tissues and cells obtained from autopsy to prospectively develop novel patient derived orthotopic xenograft (PDOX) mouse models as well as in vitro cell culture model systems for pediatric cancers, and also provide tissue samples to other researchers and organizations (eg, CBTN, DIPG Registry, COG).

Conditions

Pediatric Cancer

Outcome Measures

Primary Outcomes (1)

• Procurement of pediatric cancer and non-cancer tumor tissue during autopsy with signed consent

  Procurement of pediatric cancer and non-cancer tumor tissue during autopsy with signed consent. Tissue will be collected through a research tissue collection autopsy of the original tumor and other sites that are appropriate. Samples of both tumor and normal cells will be collected in addition to body fluids such as cerebrospinal fluid (CSF), blood, bone marrow, and skin biopsies for genomic testing.

  Up to 5 years from procurement

Study Arms (1)

Pediatric patients with cancer and non-cancer tumor types

Pediatric patients with cancer and non-cancer tumor types (solid, liquid, neuro-oncology and stem cell)

Other: Collection of post mortem tissue donation

Interventions

Collection of post mortem tissue donation OTHER

Collection of post mortem tissue from pediatric participants with cancer and non-cancer tumor types from whom post mortem tissue donation and autopsy consent is obtained.

Pediatric patients with cancer and non-cancer tumor types

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Pediatric patients with cancer and non-cancer tumor types (solid, liquid, neuro-oncology)

You may qualify if:

• Pediatric patients with cancer and non-cancer tumor types (solid, liquid, neuro-oncology)
• Signed consent for post mortem tissue donation and autopsy

You may not qualify if:

• Signed consent for post mortem tissue donation and autopsy not obtained

Sponsors & Collaborators

• Ann & Robert H Lurie Children's Hospital of Chicago: lead

Study Sites (1)

Ann & Robert H. Lurie Children's Hospital of Chicago

Chicago, Illinois, 60611, United States

RECRUITING

Related Publications (5)

• Baker JN, Windham JA, Hinds PS, Gattuso JS, Mandrell B, Gajjar P, West NK, Hammarback T, Broniscer A. Bereaved parents' intentions and suggestions about research autopsies in children with lethal brain tumors. J Pediatr. 2013 Aug;163(2):581-6. doi: 10.1016/j.jpeds.2013.01.015. Epub 2013 Feb 19.

  PMID: 23433673 BACKGROUND

• Broniscer A, Baker JN, Baker SJ, Chi SN, Geyer JR, Morris EB, Gajjar A. Prospective collection of tissue samples at autopsy in children with diffuse intrinsic pontine glioma. Cancer. 2010 Oct 1;116(19):4632-7. doi: 10.1002/cncr.25405.

  PMID: 20589749 BACKGROUND

• Wiener L, Sweeney C, Baird K, Merchant MS, Warren KE, Corner GW, Roberts KE, Lichtenthal WG. What do parents want to know when considering autopsy for their child with cancer? J Pediatr Hematol Oncol. 2014 Aug;36(6):464-70. doi: 10.1097/MPH.0000000000000078.

  PMID: 24309611 BACKGROUND

• Alabran JL, Hooper JE, Hill M, Smith SE, Spady KK, Davis LE, Peterson LS, Malempati S, Ryan CW, Acosta R, Spunt SL, Keller C. Overcoming autopsy barriers in pediatric cancer research. Pediatr Blood Cancer. 2013 Feb;60(2):204-9. doi: 10.1002/pbc.24320. Epub 2012 Sep 26.

  PMID: 23015377 BACKGROUND

• Meeting Minutes: Enhancing Biobanking for Childhood Cancers, NCI, May 13, 2019

  BACKGROUND

Related Links

• Related Info
• Related Info

Biospecimen

Retention: SAMPLES WITH DNA

Tissue will be collected through a research tissue collection autopsy of the original tumor and other sites that are appropriate. Both tumor and normal cells will be collected during autopsy in addition to body fluids such cerebrospinal fluid (CSF), blood, bone marrow and skin biopsies for genomic testing. For brain tumor bio-specimens, through CBTN, we will store, analyze and share a large cohort of samples and within the repository protocol annotate and characterize using the latest genomic technologies. The information and materials collected will be used to support cross-disciplinary collaborations and coordinated research projects, focused on the molecular and cellular origins of children's tumors.

MeSH Terms

Conditions

Neoplasms

Study Officials

• Angela Waanders, MD

  Ann & Robert H Lurie Children's Hospital of Chicago

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Angela Waanders, MD

CONTACT

312-227-4090; awaanders@luriechildrens.org

Melissa Williams, BA

CONTACT

312-227-3893; mjwilliams@luriechildrens.org

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principle Investigator

Study Record Dates

• First Submitted: November 3, 2021
• First Posted: November 15, 2021
• Study Start: August 14, 2019
• Primary Completion (Estimated): August 14, 2029
• Study Completion (Estimated): August 14, 2029
• Last Updated: November 12, 2024

Record last verified: 2024-11

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, ICF
• Time Frame: Starting August 2019
• Access Criteria: The IPD for this study will be stored in the CBTN Biorepository. Samples and data will be de-identified prior to placement in the CBTN Biorepository. Researchers who have been granted access to the CBTN Biorepository will have access to the IPD for this study.

Locations

US (1)